235 related articles for article (PubMed ID: 18231644)
21. Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany.
Dall P; Koch T; Göhler T; Selbach J; Ammon A; Eggert J; Gazawi N; Rezek D; Wischnik A; Hielscher C; Keitel S; Cirrincione U; Hinke A; Feisel-Schwickardi G
Oncologist; 2017 Feb; 22(2):131-138. PubMed ID: 28174294
[TBL] [Abstract][Full Text] [Related]
22. The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer.
Ligibel JA; Winer EP
J Natl Compr Canc Netw; 2003 Apr; 1(2):215-21. PubMed ID: 19768880
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?
Chung CT; Carlson RW
Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S18-23. PubMed ID: 15347435
[TBL] [Abstract][Full Text] [Related]
24. Subclinical Myocardial Impairment Occurred in Septal and Anterior LV Wall Segments After Anthracycline-Embedded Chemotherapy and did not Worsen During Adjuvant Trastuzumab Treatment in Breast Cancer Patients.
Lange SA; Jung J; Jaeck A; Hitschold T; Ebner B
Cardiovasc Toxicol; 2016 Apr; 16(2):193-206. PubMed ID: 26022230
[TBL] [Abstract][Full Text] [Related]
25. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
[TBL] [Abstract][Full Text] [Related]
26. Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting.
Morales L; Neven P; Paridaens R
Curr Opin Oncol; 2005 Nov; 17(6):559-65. PubMed ID: 16224233
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
Qian X; Li Z; Ruan G; Tu C; Ding W
Breast Cancer Res Treat; 2020 Jan; 179(2):275-285. PubMed ID: 31606823
[TBL] [Abstract][Full Text] [Related]
28. The curability of breast cancer and the treatment of advanced disease.
Guarneri V; Conte PF
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001.
Aapro MS
Oncologist; 2001; 6(4):376-85. PubMed ID: 11524557
[TBL] [Abstract][Full Text] [Related]
30. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
31. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer.
Lenihan DJ; Esteva FJ
Oncologist; 2008 Dec; 13(12):1224-34. PubMed ID: 19091778
[TBL] [Abstract][Full Text] [Related]
32. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.
Lin A; Rugo HS
Curr Treat Options Oncol; 2007 Feb; 8(1):47-60. PubMed ID: 17660958
[TBL] [Abstract][Full Text] [Related]
33. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
34. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer.
Diaby V; Tawk R; Sanogo V; Xiao H; Montero AJ
Breast Cancer Res Treat; 2015 May; 151(1):27-40. PubMed ID: 25893588
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy.
Chen DH; Tyebally S; Malloupas M; Roylance R; Spurrell E; Raja F; Ghosh AK
Curr Cardiol Rep; 2021 Jan; 23(3):16. PubMed ID: 33501515
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
37. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early stage breast cancer.
Ligibel JA; Winer EP
Womens Health (Lond); 2006 Jan; 2(1):89-97. PubMed ID: 19803930
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
39. Ongoing adjuvant trials with trastuzumab in breast cancer.
Tan AR; Swain SM
Semin Oncol; 2003 Oct; 30(5 Suppl 16):54-64. PubMed ID: 14613027
[TBL] [Abstract][Full Text] [Related]
40. An update on adjuvant systemic therapy for elderly patients with early breast cancer.
Jerzak KJ; Desautels DN; Pritchard KI
Expert Opin Pharmacother; 2016 Oct; 17(14):1881-8. PubMed ID: 27539883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
